| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 521,870 | 598,912 | ||
| Accounts receivable | 1,970 | 1,936 | ||
| Prepaid expenses and other current assets | 49,706 | 50,915 | ||
| Total current assets | 573,546 | 651,763 | ||
| Property and equipment, net | 632 | 737 | ||
| Other assets | 8,781 | 8,940 | ||
| Total assets | 582,959 | 661,440 | ||
| Accounts payable | 6,916 | 7,843 | ||
| Accrued expenses and other current liabilities | 56,338 | 45,057 | ||
| Total current liabilities | 63,254 | 52,900 | ||
| Total liabilities | 63,254 | 52,900 | ||
| Preferred stock-Series APreferred Stock | 0 | 0 | ||
| Preferred stock-Preferred Stock Excluding Series APreferred Stock | 0 | 0 | ||
| Common stock, par value 0.0001 per share, 500,000,000 shares authorized, 174,532,710 shares issued and outstanding at september30, 2025 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at march31, 2025 | 17 | 16 | ||
| Additional paid-in capital | 2,004,876 | 1,966,923 | ||
| Accumulated other comprehensive income | 1,450 | 1,737 | ||
| Accumulated deficit | -1,486,638 | -1,360,136 | ||
| Total stockholders equity | 519,705 | 608,540 | ||
| Total liabilities and stockholders equity | 582,959 | 661,440 | ||
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)